Welcome to our dedicated page for Mannkind news (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind stock.
MannKind Corporation reports developments across its biopharmaceutical business in cardiometabolic and orphan lung diseases. Company updates center on commercial products such as Afrezza, an inhaled insulin for diabetes, and Furoscix, a furosemide injection for fluid overload in heart failure and chronic kidney disease, as well as financial results, product demand, launch infrastructure and capital-structure actions.
MannKind news also covers dry powder inhalation programs and drug-device combinations, including work using its Technosphere platform. Recurring topics include Afrezza clinical and real-world data, Furoscix device and regulatory updates, Nintedanib DPI for idiopathic pulmonary fibrosis, ralinepag DPI collaboration activity with United Therapeutics, and other pipeline decisions affecting inhaled therapies.
MannKind (Nasdaq: MNKD), together with Alfred E. Mann Charities and The Diabetes Link, launched the Centennial Al Mann Scholarship on Nov 6, 2025 to mark Alfred E. Mann’s 100th birthday.
The program will distribute $100,000 to at least 10 students living with diabetes pursuing 2- or 4-year life sciences degrees, with awards up to $10,000 per student paid in annual installments of $2,500 over two to four years. The first awards target the 2026 academic year and the application window opens in early 2026; details and an early interest form will be available at thediabeteslink.org.
MannKind (NASDAQ: MNKD) reported Q3 2025 revenue $82.1M (+17% YoY) and YTD revenue $237.0M (+14% YoY). The company completed the acquisition of scPharmaceuticals on October 7, 2025 to accelerate FUROSCIX revenue growth and used ~$133.2M cash plus a $250M delayed-draw term loan in October to fund the transaction.
Pipeline and regulatory milestones include FDA acceptance of the Afrezza pediatric sBLA with a PDUFA date of May 29, 2026, submission of a FUROSCIX ReadyFlow Autoinjector sNDA, MNKD-101 Phase 3 enrollment ahead of schedule, and initiation of an IPF Phase 2 trial (MNKD-201).
MannKind (Nasdaq: MNKD) will release its third quarter 2025 financial results before the market opens on November 5, 2025. The company will host a webcast at 9:00 a.m. Eastern Time the same day to discuss results and provide a business update.
Investors can access the live webcast and a replay via the company’s investor website at https://investors.mannkindcorp.com/events-and-presentations; the replay will be available within 24 hours and remain accessible for approximately 90 days.
MannKind (NASDAQ: MNKD) announced the U.S. FDA has accepted its supplemental biologics license application (sBLA) seeking approval of Afrezza inhaled insulin for children and adolescents aged 4–17 with type 1 or type 2 diabetes.
The submission is based on results from the Phase 3 INHALE-1 trial (26-week open-label, randomized) and its 26-week extension; topline results were reported in December 2024. The FDA assigned a PDUFA target action date of May 29, 2026. Full results will be presented at ISPAD in early November. Afrezza is already FDA-approved for adults (18+ since June 2014) and approved in India and Brazil.
MannKind (Nasdaq: MNKD) completed its acquisition of scPharmaceuticals on October 7, 2025, creating a cardiometabolic-focused commercial platform. The deal consideration was $5.35 per share in cash plus one non-tradable contingent value right (CVR) for up to $1.00, for total consideration of up to $6.35 per share. MannKind cited an annualized revenue run rate of over $370 million based on Q2 2025 results, driven by Afrezza, FUROSCIX, V-Go and Tyvaso DPI–related revenues. The FUROSCIX ReadyFlow autoinjector supplemental NDA was filed in Q3 2025. Following a merger under Delaware law, scPharmaceuticals became a wholly owned subsidiary and its Nasdaq symbol SCPH ceased trading.
MannKind Corporation (Nasdaq: MNKD), a developer of inhaled therapeutic products for endocrine and orphan lung diseases, has appointed Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer, effective September 29, 2025.
Dr. Ahuja brings over 20 years of biopharmaceutical leadership experience, most recently serving as Development and Launch Leader at Kardigan Bio. His extensive background includes senior roles at Idorsia Pharmaceuticals, Allergan, Takeda, Pfizer, and Novartis. Dr. Ahuja holds an MD from Washington University and an MBA from Harvard Business School, and practiced medicine at Boston Children's Hospital for over a decade.
MannKind Corporation (Nasdaq: MNKD), a developer of inhaled therapeutic products for endocrine and orphan lung diseases, has announced its participation in four upcoming investor conferences in September 2025.
CEO Michael Castagna and CFO Chris Prentiss will present at the Wells Fargo Health Care Conference (Sept. 3), Cantor Global Healthcare Conference (Sept. 4), H.C. Wainwright Global Investment Conference (Sept. 9), and Morgan Stanley Global Healthcare Conference (Sept. 9). Live webcasts will be available on MannKind's investor relations website, with recordings accessible for 90 days post-event.
MannKind Corporation (NASDAQ: MNKD) has expanded its collaboration with United Therapeutics (NASDAQ: UTHR) to develop a second dry powder inhalation therapy. This follows their successful partnership that resulted in Tyvaso DPI, the first FDA-approved dry powder inhalation treatment for pulmonary hypertension.
Under the expanded agreement, MannKind will utilize its Technosphere® platform to formulate a new investigational molecule, while United Therapeutics will handle preclinical and clinical development. The deal includes an upfront payment of $5 million to MannKind, potential development milestones up to $35 million, and 10% royalties on net sales of any resulting product.
MannKind Corporation (Nasdaq: MNKD) has announced the acquisition of scPharmaceuticals in a deal valued up to $360 million. The transaction includes an upfront payment of $5.35 per share plus a CVR worth up to $1.00 per share tied to regulatory and sales milestones.
The acquisition brings FUROSCIX, an FDA-approved treatment for fluid overload in chronic heart failure and chronic kidney disease patients, with a $10+ billion U.S. market opportunity. scPharmaceuticals reported strong H1 2025 performance with net sales of $27.8 million, up 96% year-over-year. The combined company projects an annualized revenue run rate of over $370 million based on Q2 2025 results.
The deal is expected to close in Q4 2025, with Blackstone providing $175 million in additional funding. A FUROSCIX ReadyFlow Autoinjector sNDA submission is planned for Q3 2025, potentially reducing treatment time from five hours to under 10 seconds.
MannKind Corporation (Nasdaq: MNKD) has secured a strategic financing agreement worth up to $500 million with Blackstone. The deal includes a $75 million initial term loan at closing, a $125 million delayed draw term loan available for 24 months, and an additional $300 million uncommitted DDTL.
The non-dilutive financing, maturing in August 2030, bears interest at SOFR plus 4.75%. The funds will support MannKind's growth initiatives, including the commercial team expansion for Afrezza's potential pediatric indication, pipeline advancement, and business development opportunities.